文献速递新发突发、热带与寄生虫病

在加蓬学龄儿童中联合接种Na-APR-1和Na-GST-1钩虫疫苗的安全性和免疫原性:一项随机、对照、观察者盲法、1期、剂量递增试验

Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial.
PubMed 文献 · Lancet Infect Dis · 2024-03-18

在加蓬钩虫流行区60名6-10岁健康儿童中开展随机、对照、观察者盲法1期剂量递增试验,按4:1随机联合接种Na-GST-1/Na-APR-1(M74)疫苗或乙肝疫苗加生理盐水安慰剂,疫苗组内再按1:1随机接受0、2、4月或0、2、6月程序。联合接种耐受良好,未观察到疫苗相关严重不良事件,两种抗原均诱导剂量依赖性IgG应答,0、2、6月程序诱导的IgG应答显著更高。

要点

  • 联合接种疫苗耐受良好,最常见征集性不良事件为轻至中度注射部位疼痛。
  • 未观察到疫苗相关严重不良事件。
  • 0、2、6月程序诱导的抗Na-APR-1(M74)和抗Na-GST-1 IgG应答显著高于0、2、4月程序。

核心结论

  • 在加蓬学龄儿童中联合接种重组Na-APR-1(M74)和Na-GST-1耐受良好并诱导显著IgG应答。
  • 作者认为这些结果支持在钩虫流行区进一步开展该抗原组合的概念验证性控制感染和效力研究。

研究设计与样本

  • 随机、对照、观察者盲法、1期、剂量递增试验,在加蓬Lambaréné的临床研究中心开展。
  • 纳入60名6-10岁健康儿童,按4:1随机分配至联合接种Na-GST-1/Alhydrogel加Na-APR-1(M74)/Alhydrogel加GLA-AF组或联合接种ENGERIX-B乙肝疫苗加生理盐水安慰剂组。
  • 疫苗组内按1:1随机分配至0、2、4月或0、2、6月两种免疫程序。
  • 第一、第二、第三队列分别给予每种抗原10 μg、30 μg、100 μg。
  • 安全性分析采用意向治疗人群,免疫原性分析采用符合方案人群(完成所有计划接种的儿童)。

主要发现

  • 联合接种耐受良好,最常见的征集性不良事件为轻至中度注射部位疼痛,每个疫苗组最多12例(75%)/16例。
  • 轻度头痛12例(25%)/48例,发热11例(23%)/48例。
  • 未观察到疫苗相关严重不良事件。
  • 抗Na-APR-1(M74)和抗Na-GST-1 IgG以剂量依赖方式显著诱导,无论剂量如何,峰值均见于第三次接种后14天。
  • 0、2、6月程序与0、2、4月程序相比,Na-APR-1(M74)几何平均水平分别为2295.97 AU和726.89 AU,Na-GST-1几何平均水平分别为331.2 AU和21.4 AU。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A human hookworm vaccine is being developed to protect children against iron deficiency and anaemia associated with chronic infection with hookworms. Necator americanus aspartic protease-1 (Na-APR-1) and N americanus glutathione S-transferase-1 (Na-GST-1) are components of the blood digestion pathway critical to hookworm survival in the host. Recombinant Na-GST-1 and catalytically inactive Na-APR-1 (Na-APR-1[M74]) adsorbed to Alhydrogel were safe and immunogenic when delivered separately or co-administered to adults in phase 1 trials in non-endemic and endemic areas. We aimed to investigate the safety and immunogenicity of these antigens in healthy children in a hookworm-endemic area. METHODS: This was a randomised, controlled, observer-blind, phase 1, dose-escalation trial, conducted in a clinical research centre, in 60 children aged six to ten years in Lambaréné, a hookworm-endemic region of Gabon. Healthy children (determined by clinical examination and safety laboratory testing) were randomised 4:1 to receive co-administered Na-GST-1 on Alhydrogel plus Na-APR-1(M74) on Alhydrogel and glucopyranosyl lipid A in aqueous formulation (GLA-AF), or co-administered ENGERIX-B hepatitis B vaccine (HBV) and saline placebo, injected into the deltoid of each arm. Allocation to vaccine groups was observer-masked. In each vaccine group, children were randomised 1:1 to receive intramuscular injections into each deltoid on two vaccine schedules, one at months 0, 2, and 4 or at months 0, 2, and 6. 10 μg, 30 μg, and 100 μg of each antigen were administered in the first, second, and third cohorts, respectively. The intention-to-treat population was used for safety analyses; while for immunogenicity analyses, the per-protocol population was used (children who received all scheduled vaccinations). The primary outcome was to evaluate the vaccines' safety and reactogenicity in healthy children aged between six and ten years. The secondary outcome was to measure antigen-specific serum IgG antibody levels at pre-vaccination and post-vaccination timepoints by qualified ELISAs. The trial is registered with ClinicalTrials.gov, NCT02839161, and is completed. FINDINGS: Between Jan 23 and Oct 3, 2017, 137 children were screened, of whom 76 were eligible for this trial. 60 children were recruited, and allocated to either 10 μg of the co-administered antigens (n=8 for each injection schedule), 30 μg (n=8 for each schedule), 100 μg (n=8 for each schedule), or HBV and placebo (n=6 for each schedule) in three sequential cohorts. Co-administration of the vaccines was well tolerated; the most frequent solicited adverse events were mild-to-moderate injection-site pain, observed in up to 12 (75%) of 16 participants per vaccine group, and mild headache (12 [25%] of 48) and fever (11 [23%] of 48). No vaccine-related serious adverse events were observed. Significant anti-Na-APR-1(M74) and anti-Na-GST-1 IgG levels were induced in a dose-dependent manner, with peaks seen 14 days after the third vaccinations, regardless of dose (for Na-APR-1[M74], geometric mean levels [GML]=2295·97 arbitrary units [AU] and 726·89 AU, while for Na-GST-1, GMLs=331·2 AU and 21·4 AU for the month 0, 2, and 6 and month 0, 2, and 4 schedules, respectively). The month 0, 2, and 6 schedule induced significantly higher IgG responses to both antigens (p=0·01 and p=0·04 for Na-APR-1[M74] and Na-GST-1, respectively). INTERPRETATION: Co-administration of recombinant Na-APR-1(M74) and Na-GST-1 to school-aged Gabonese children was well tolerated and induced significant IgG responses. These results justify further evaluation of this antigen combination in proof-of-concept controlled-infection and efficacy studies in hookworm-endemic areas. FUNDING: European Union Seventh Framework Programme.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zinsou JF, Diemert DJ, Dejon-Agobé JC, et al. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial. Lancet Infect Dis. 2024. PMID: 38513684. doi:10.1016/S1473-3099(24)00104-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。